Veracyte initiates study on breast cancer genomic tests

By staff writers

September 11, 2020 -- Veracyte has started a European consensus study that will explore the medical utility of multiple breast cancer genomic tests. Coordinated by Dr. Giuseppe Curigliano, PhD, from the European Institute of Oncology in Milan, the Procure study will have input from 180 breast cancer clinicians practicing in 12 countries.

As of yet, there is no consensus in the breast cancer community about the utility and ideal application of genomic tests. Curigliano and colleagues will use the Delphi method to facilitate consensus, which includes at least two rounds of a structured questionnaire. Consensus is reached by grouping participants' responses after each wave of questioning.

Over approximately 12 months, the study will comprehensively evaluate the existing evidence supporting the use of breast cancer genomic tests and the added value that clinicians attribute to them. The researchers will also assess the current use of these tools in patients with differing clinical-pathological profiles, establish recommendations on their use, and discuss future clinical applications and research opportunities.

Veracyte touts Percepta clinical trial results
Veracyte is highlighting clinical trial results published August 3 in Chest that show its Percepta classifier can reduce the need for subsequent...
Veracyte, CareDx partner for transplant rejection testing
CareDx will become the exclusive commercialization partner for solid organ transplant rejection tests that run on Veracyte's nCounter Flex Analysis System...
Veracyte licenses gene signature for idiopathic pulmonary fibrosis
Veracyte has licensed exclusive rights to a 52-gene signature for idiopathic pulmonary fibrosis from Yale University and plans to develop a blood test...
Veracyte licenses NanoString diagnostic platform in $50M deal
Veracyte is set to pay $50 million -- $40 million in cash and the rest in common stock -- for an exclusive global license to the NanoString...
Veracyte nasal swab test holds its own in lung cancer detection
Veracyte said the accuracy of its investigational nasal swab genomic classifying test rivals the clinical standard for lung nodule assessment and has...

Copyright © 2020

Last Updated np 9/15/2020 4:33:11 PM

Register below for our weekly Letter from the Editor to receive the latest Clinical Lab news and insights.